MD NET: Pediatric

MD NET：儿科

• 批准号: 10048432
• 负责人: RALPH PARCHMENT
• 金额: $ 475.51万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10048432
• 关键词: Acute Myelocytic Leukemia; Adult; Area; Authorization documentation; Biological Assay; Biological Markers; Categories; Characteristics; Childhood; Clinical; Clinical Data; Clinical Protocols; Clinical Trials; Contracts; Data; Data Files; Diagnostic; Division of Cancer Treatment and Diagnosis; Dysmyelopoietic Syndromes; Eligibility Determination; Enrollment; Future; Generations; Genotype; Goals; Immune; Institute of Medicine (U.S.); Laboratories; Molecular Profiling; Molecular Target; National Clinical Trials Network; Oncogenic; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Physicians; Protocols documentation; Publications; Regulation; Relapse; Reporting; Reproducibility; Residual Neoplasm; Residual state; Resistance; Selection for Treatments; Site; Specimen; Structure; Testing; Therapeutic; Vendor; Work; adolescent patient; base; biobank; data access; data warehouse; leukemia; longitudinal analysis; predictive signature; profiles in patients; resistance mechanism; response; sample collection; treatment optimization; young adult

The Division of Cancer Treatment and Diagnosis, NCI (DCTD) has embarked on a strategic initiative in its National Clinical Trials Network (NCTN) to define and discover new treatments for patients with Acute Myelogenous Leukemia/Myelodysplastic Syndrome (AML/MDS). As described in a recent report from the Institute of Medicine ‘treatment for these patients has not changed in a substantive way in the last 40 years’ demonstrating that advances in this area are critically needed. The primary goal of this initiative is to optimize therapeutic strategies for adult, young adult, and adolescent patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes (AML/MDS). This includes: • A master screening protocol that evaluates patients for assignment to clinical trials. • A data support structure that allows longitudinal analysis of sensitivity and resistance biomarkers in leukemia for discovery of new molecular targets • Deciphering clonal selection in minimal residual disease • Understanding mechanisms of resistance and response to therapy The long-term goals of the study are to: • Identify biomarkers with the potential to optimize therapy selection in AML/MDS. • Define molecular signatures that predict different response categories in AML/MDS. • Define phenotype/genotype characteristics of response/resistance in AML/MDS that will be valid for diverse or specific classes of drugs with different mechanisms of action. • To identify targets in minimal residual disease (MRD), including targets in relapse and to identify new ways to eradicate MRD.

NCI癌症治疗和诊断部（DCTD）在其国家临床试验网络（NCTN）中启动了一项战略举措，以确定和发现急性髓性白血病/骨髓增生异常综合征（AML/MDS）患者的新治疗方法。正如医学研究所最近的一份报告所描述的那样，“在过去的40年里，对这些患者的治疗并没有实质性的改变”，这表明迫切需要在这一领域取得进展。